{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:54:40Z","timestamp":1788522880398,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schizophr"],"DOI":"10.1038\/s41537-025-00567-4","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:26:10Z","timestamp":1738949170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of identifying Treatment-Resistant and non-Treatment-Resistant Schizophrenia using niacin skin flushing response combined with clinical feature"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-2897","authenticated-orcid":false,"given":"Jizhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"567_CR1","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi, M. et al. Incidence, prevalence, and global burden of schizophrenia\u2014data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol. Psychiatry 28, 5319\u20135327 (2023).","journal-title":"Mol. Psychiatry"},{"key":"567_CR2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","volume":"50","author":"RR Conley","year":"2001","unstructured":"Conley, R. R. & Kelly, D. L. Management of treatment resistance in schizophrenia. Biol. Psychiatry 50, 898\u2013911 (2001).","journal-title":"Biol. Psychiatry"},{"key":"567_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pnpbp.2015.08.010","volume":"65","author":"F Iasevoli","year":"2016","unstructured":"Iasevoli, F. et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog. Neuropsychopharmacol. Biol. Psychiatry 65, 34\u201348 (2016).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"567_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","volume":"29","author":"JL Kennedy","year":"2014","unstructured":"Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I. & Hornberger, J. C. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int. Clin. Psychopharmacol. 29, 63\u201376 (2014).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"567_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S2215-0366(15)00575-1","volume":"3","author":"T Wimberley","year":"2016","unstructured":"Wimberley, T. et al. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry 3, 358\u2013366 (2016).","journal-title":"Lancet Psychiatry"},{"key":"567_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1017\/S0033291719002083","volume":"51","author":"SE Smart","year":"2021","unstructured":"Smart, S. E., K\u0119pi\u0144ska, A. P., Murray, R. M. & MacCabe, J. H. Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. Psychol. Med. 51, 44\u201353 (2021).","journal-title":"Psychol. Med."},{"key":"567_CR7","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1017\/S0033291716002014","volume":"46","author":"J Lally","year":"2016","unstructured":"Lally, J. et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol. Med. 46, 3231\u20133240 (2016).","journal-title":"Psychol. Med."},{"key":"567_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","volume":"16","author":"M Carbon","year":"2014","unstructured":"Carbon, M. & Correll, C. U. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin. Neurosci. 16, 505\u2013524 (2014).","journal-title":"Dialogues Clin. Neurosci."},{"key":"567_CR9","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","volume":"44","author":"H Takeuchi","year":"2019","unstructured":"Takeuchi, H. et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology 44, 1036\u20131042 (2019).","journal-title":"Neuropsychopharmacology"},{"key":"567_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","volume":"138","author":"R Emsley","year":"2012","unstructured":"Emsley, R., Nuamah, I., Hough, D. & Gopal, S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr. Res. 138, 29\u201334 (2012).","journal-title":"Schizophr. Res."},{"key":"567_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbrc.2006.04.051","volume":"345","author":"Y Tang","year":"2006","unstructured":"Tang, Y. et al. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem. Biophys. Res. Commun. 345, 29\u201337 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"567_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0163-7827(03)00037-7","volume":"43","author":"M Murakami","year":"2004","unstructured":"Murakami, M. & Kudo, I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog. Lipid Res. 43, 3\u201335 (2004).","journal-title":"Prog. Lipid Res"},{"key":"567_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","volume":"81","author":"E Lai","year":"2007","unstructured":"Lai, E. et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 81, 849\u2013857 (2007).","journal-title":"Clin. Pharmacol. Ther."},{"key":"567_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.psychres.2006.10.002","volume":"152","author":"C-M Liu","year":"2007","unstructured":"Liu, C.-M. et al. Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. Psychiatry Res. 152, 181\u2013187 (2007).","journal-title":"Psychiatry Res."},{"key":"567_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/schbul\/sbm153","volume":"35","author":"S-S Chang","year":"2009","unstructured":"Chang, S.-S. et al. Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading. Schizophr. Bull. 35, 213\u2013221 (2009).","journal-title":"Schizophr. Bull."},{"key":"567_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.schres.2010.03.025","volume":"122","author":"E Messamore","year":"2010","unstructured":"Messamore, E., Hoffman, W. F. & Yao, J. K. Niacin sensitivity and the arachidonic acid pathway in schizophrenia. Schizophr. Res. 122, 248\u2013256 (2010).","journal-title":"Schizophr. Res."},{"key":"567_CR17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/schbul\/sbx150","volume":"44","author":"L Sun","year":"2018","unstructured":"Sun, L. et al. Identification of the niacin-blunted subgroup of schizophrenia patients from mood disorders and healthy individuals in Chinese population. Schizophr. Bull. 44, 896\u2013907 (2018).","journal-title":"Schizophr. Bull."},{"key":"567_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.schres.2021.02.009","volume":"230","author":"D-D Wang","year":"2021","unstructured":"Wang, D.-D. et al. Attenuated and delayed niacin skin flushing in schizophrenia and affective disorders: a potential clinical auxiliary diagnostic marker. Schizophr. Res. 230, 53\u201360 (2021).","journal-title":"Schizophr. Res."},{"key":"567_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.schres.2021.06.028","volume":"243","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. A potential objective marker in first-episode schizophrenia based on abnormal niacin response. Schizophr. Res. 243, 405\u2013412 (2022).","journal-title":"Schizophr. Res."},{"key":"567_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261\u2013276 (1987).","journal-title":"Schizophr. Bull."},{"key":"567_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph, C., Tierney, M. C., Mohr, E. & Chase, T. N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 20, 310\u2013319 (1998).","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"567_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00005053-198901000-00007","volume":"177","author":"JP McEvoy","year":"1989","unstructured":"McEvoy, J. P. et al. Insight in schizophrenia. Its relationship to acute psychopathology. J. Nerv. Ment. Dis. 177, 43\u201347 (1989).","journal-title":"J. Nerv. Ment. Dis."},{"key":"567_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jad.2022.12.017","volume":"324","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Identification of adolescent patients with depression via assessment of the niacin skin flushing response. J. Affect. Disord. 324, 69\u201376 (2023).","journal-title":"J. Affect. Disord."},{"key":"567_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jad.2023.10.151","volume":"345","author":"S Li","year":"2024","unstructured":"Li, S. et al. Omega-3 supplementation improves depressive symptoms, cognitive function and niacin skin flushing response in adolescent depression: a randomized controlled clinical trial. J. Affect. Disord. 345, 394\u2013403 (2024).","journal-title":"J. Affect. Disord."},{"key":"567_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.plefa.2005.02.007","volume":"72","author":"S Smesny","year":"2005","unstructured":"Smesny, S. et al. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. Prostagland. Leukot. Essent. Fat. acids 72, 393\u2013402 (2005).","journal-title":"Prostagland. Leukot. Essent. Fat. acids"},{"key":"567_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jpsychires.2004.01.007","volume":"38","author":"S Smesny","year":"2004","unstructured":"Smesny, S. et al. The influence of age and gender on niacin skin test results\u2014implications for the use as a biochemical marker in schizophrenia. J. Psychiatr. Res. 38, 537\u2013543 (2004).","journal-title":"J. Psychiatr. Res."},{"key":"567_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0022-3956(03)00006-2","volume":"37","author":"S Smesny","year":"2003","unstructured":"Smesny, S. et al. Potential use of the topical niacin skin test in early psychosis\u2014a combined approach using optical reflection spectroscopy and a descriptive rating scale. J. Psychiatr. Res. 37, 237\u2013247 (2003).","journal-title":"J. Psychiatr. Res."},{"key":"567_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0920-9964(00)00082-7","volume":"50","author":"SD Turenne","year":"2001","unstructured":"Turenne, S. D., Seeman, M. & Ross, B. M. An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. Schizophr. Res. 50, 191\u2013197 (2001).","journal-title":"Schizophr. Res."},{"key":"567_CR29","first-page":"163","volume":"43","author":"SH Shah","year":"2000","unstructured":"Shah, S. H., Vankar, G. K., Peet, M. & Ramchand, C. N. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr. Res. 43, 163\u2013164 (2000).","journal-title":"Schizophr. Res."},{"key":"567_CR30","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1176\/appi.ps.201100435","volume":"63","author":"JI Manuel","year":"2012","unstructured":"Manuel, J. I., Essock, S. M., Wu, Y., Pangilinan, M. & Stroup, S. Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. Psychiatr. Serv. (Wash., DC) 63, 1146\u20131149 (2012).","journal-title":"Psychiatr. Serv. (Wash., DC)"},{"key":"567_CR31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.euroneuro.2012.03.003","volume":"22","author":"J Nielsen","year":"2012","unstructured":"Nielsen, J., R\u00f8ge, R., Schjerning, O., S\u00f8rensen, H. J. & Taylor, D. Geographical and temporal variations in clozapine prescription for schizophrenia. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 22, 818\u2013824 (2012).","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"567_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1176\/appi.ps.201300180","volume":"65","author":"TS Stroup","year":"2014","unstructured":"Stroup, T. S., Gerhard, T., Crystal, S., Huang, C. & Olfson, M. Geographic and clinical variation in clozapine use in the United States. Psychiatr. Serv. (Wash., DC) 65, 186\u2013192 (2014).","journal-title":"Psychiatr. Serv. (Wash., DC)"},{"key":"567_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/eip.12412","volume":"11","author":"J Immonen","year":"2017","unstructured":"Immonen, J., J\u00e4\u00e4skel\u00e4inen, E., Korpela, H. & Miettunen, J. Age at onset and the outcomes of schizophrenia: a systematic review and meta-analysis. Early Interv. Psychiatry 11, 453\u2013460 (2017).","journal-title":"Early Interv. Psychiatry"},{"key":"567_CR34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ebiom.2017.04.002","volume":"18","author":"R Hilker","year":"2017","unstructured":"Hilker, R. et al. Is an early age at illness onset in schizophrenia associated with increased genetic susceptibility? Analysis of data from the Nationwide Danish Twin Register. EBioMedicine 18, 320\u2013326 (2017).","journal-title":"EBioMedicine"},{"key":"567_CR35","doi-asserted-by":"publisher","first-page":"s19","DOI":"10.1192\/bjp.181.43.s19","volume":"43","author":"M Byrne","year":"2002","unstructured":"Byrne, M., Agerbo, E. & Mortensen, P. B. Family history of psychiatric disorders and age at first contact in schizophrenia: an epidemiological study. Br. J. Psychiatry Suppl. 43, s19\u2013s25 (2002).","journal-title":"Br. J. Psychiatry Suppl."},{"key":"567_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/schbul\/sbv130","volume":"42","author":"JK Yao","year":"2016","unstructured":"Yao, J. K. et al. Prevalence and specificity of the abnormal niacin response: a potential endophenotype marker in schizophrenia. Schizophr. Bull. 42, 369\u2013376 (2016).","journal-title":"Schizophr. Bull."},{"key":"567_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","volume":"209","author":"D Siskind","year":"2016","unstructured":"Siskind, D., McCartney, L., Goldschlager, R. & Kisely, S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry: J. Ment. Sci. 209, 385\u2013392 (2016).","journal-title":"Br. J. Psychiatry: J. Ment. Sci."},{"key":"567_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40263-017-0411-6","volume":"31","author":"DM Taylor","year":"2017","unstructured":"Taylor, D. M. Clozapine for treatment-resistant schizophrenia: still the gold standard? CNS Drugs 31, 177\u2013180 (2017).","journal-title":"CNS Drugs"},{"key":"567_CR39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","volume":"201","author":"OD Howes","year":"2012","unstructured":"Howes, O. D. et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br. J. Psychiatry: J. Ment. Sci. 201, 481\u2013485 (2012).","journal-title":"Br. J. Psychiatry: J. Ment. Sci."}],"container-title":["Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00567-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00567-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00567-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:26:12Z","timestamp":1738949172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00567-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["567"],"URL":"https:\/\/doi.org\/10.1038\/s41537-025-00567-4","relation":{},"ISSN":["2754-6993"],"issn-type":[{"value":"2754-6993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Human Ethics Committee of the Second Xiangya Hospital of Central South University. All procedures were performed in accordance with the study protocol and ethical guidelines and regulations. Informed consent was obtained from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and ethics committee approval"}}],"article-number":"15"}}